New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

RHHBY

Change to the Roche Enlarged Corporate Executive Committee

RHHBY

Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

RHHBY

Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

RHHBY

Roche’s momentum in digital pathology continues with FDA clearance on its high-volume slide scanner

The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to...

RHHBY

Roche purchases shares in tender offer for Poseida Therapeutics, Inc.

Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Blue Giant...

RHHBY

Roche Vabysmo Sales Surpassed USD 4 Billion In 2024

Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research Vabysmo Sales Accounts For More...

This website automatically aggregates content from various other websites. The copyright of content and images belongs to those websites and their respective companies. We are not responsible for the content published here. Please ensure that all information is for reference only and not investment advice. However, we will strive to strictly control content that provides no value or brings negativity to the community.

No Result

View All Result

New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

Change to the Roche Enlarged Corporate Executive Committee

Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

RHHBY

Roche’s momentum in digital pathology continues with FDA clearance on its high-volume slide scanner

Roche purchases shares in tender offer for Poseida Therapeutics, Inc.

Roche Vabysmo Sales Surpassed USD 4 Billion In 2024

Recent Posts

Recent Comments